SEI Investments’s Coherus Oncology CHRS Stock Holding History

SEI Investments’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$107K	Sell	76,629 -377,134	-83%	-$616K	﹤0.01%	3172
2026 Q1	$767K	Buy	453,763 +377,134	+492%	+$670K	﹤0.01%	2481
2025 Q4	$109K	Buy	+76,629	New	+$112K	﹤0.01%	3001
2024 Q4	–	Sell	-342,427	Closed	-$356K	–	2736
2024 Q3	$356K	Sell	342,427 -12,965	-4%	-$17.8K	﹤0.01%	2293
2024 Q2	$615K	Sell	355,392 -1,586	-0.4%	-$3.19K	﹤0.01%	2086
2024 Q1	$853K	Sell	356,978 -8,444	-2%	-$20.8K	﹤0.01%	1941
2023 Q4	$1.22M	Sell	365,422 -473,695	-56%	-$1.27M	﹤0.01%	1807
2023 Q3	$3.14M	Sell	839,117 -12,548	-1%	-$58K	0.01%	1382
2023 Q2	$3.64M	Buy	851,665 +115,146	+16%	+$679K	0.01%	1353
2023 Q1	$5.04M	Buy	736,519 +59,001	+9%	+$458K	0.01%	1183
2022 Q4	$5.37M	Buy	677,518 +14,558	+2%	+$112K	0.01%	1021
2022 Q3	$6.37M	Buy	662,960 +873	+0.1%	+$8.83K	0.01%	981
2022 Q2	$4.79M	Buy	662,087 +35,993	+6%	+$313K	0.01%	1115
2022 Q1	$8.08M	Buy	626,094 +88,162	+16%	+$1.12M	0.02%	861
2021 Q4	$8.59M	Buy	537,932 +193,917	+56%	+$3.39M	0.02%	873
2021 Q3	$5.53M	Sell	344,015 -14,972	-4%	-$219K	0.01%	1028
2021 Q2	$4.96M	Sell	358,987 -562	-0.2%	-$7.96K	0.01%	1078
2021 Q1	$5.25M	Buy	359,549 +45,440	+14%	+$771K	0.01%	991
2020 Q4	$5.46M	Buy	314,109 +108,329	+53%	+$1.93M	0.01%	933
2020 Q3	$3.77M	Buy	205,780 +96,528	+88%	+$1.8M	0.01%	1002
2020 Q2	$1.95M	Buy	109,252 +90,310	+477%	+$1.53M	0.01%	1276
2020 Q1	$311K	Sell	18,942 -7,516	-28%	-$139K	﹤0.01%	1921
2019 Q4	$477K	Sell	26,458 -7,116	-21%	-$131K	﹤0.01%	1951
2019 Q3	$684K	Sell	33,574 -12,870	-28%	-$257K	﹤0.01%	1743
2019 Q2	$1.03M	Buy	+46,444	New	+$807K	﹤0.01%	1594
2018 Q1	–	Sell	-38	Closed	–	–	3483
2017 Q4	$0	Hold	38	–	–	﹤0.01%	3347
2017 Q3	$1K	Buy	+38	New	+$503	﹤0.01%	3047
2015 Q4	–	Sell	-9,773	Closed	-$196K	–	2536
2015 Q3	$196K	Buy	+9,773	New	+$297K	﹤0.01%	1611

Other funds holding CHRS

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return

SEI Investments's CHRS Position: Q2 2026 in Review

SEI Investments reduced its Coherus Oncology (CHRS) stake by 83% in Q2 2026, selling an estimated $616K and leaving 76,629 shares worth $107K. The position accounts for ﹤0.01% of the portfolio, ranked #3172.

SEI Investments first reported a position in CHRS in Q3 2015 and has held it in 28 quarters since. The position peaked at $8.59M in Q4 2021. 146 funds tracked by Wall St. Rank hold CHRS as of Q2 2026.

SEI Investments held 76,629 shares of Coherus Oncology worth $107K as of Q2 2026.
SEI Investments sold 377,134 Coherus Oncology shares in Q2 2026, an estimated $616K.
Coherus Oncology made up ﹤0.01% of SEI Investments's portfolio in Q2 2026, its #3172 holding.
SEI Investments first reported a position in Coherus Oncology in Q3 2015 and has held it in 28 quarters since.
SEI Investments's Coherus Oncology position peaked at $8.59M in Q4 2021.
146 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2026.

Based on SEI Investments's 13F filing for Q2 2026, filed 14 Aug 2026.